Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Amag, Uniqa (16/02/2023)

19.02.2023

Marinomed: Marinomed Biotech AG, listed on the Vienna Stock Exchange, achieved a further increase in demand for Carragelose products in 2022. According to preliminary figures, Carragelose revenues were up by 15.5% to € 11.2 m (2021: € 9.7 m). This positive development resulted in stable preliminary revenues of € 11.3 m for the full year (2021: € 11.6 m) despite the lack of milestone payments in 2022. Adjusted for the Budesolv milestone payment of € 1.9 m in 2021, revenues have increased by 16.5 %. Cash and cash equivalents increased to € 8.2 m (2021: € 5.8 m; +41%), reflecting a low cash burn-rate throughout 2022 due to profitable revenues and inflows from loans, real estate financings and the convertible bond program with Nice & Green.
Marinomed Biotech: weekly performance: 7.21%

Amag: Amag Austria Metall AG again achieved record levels of revenue and earnings following record results in the previous year. CEO  Gerald Mayer comments: “With our proven strategic focus on innovation and sustainability and with our expert team, we mastered the challenges over the past year and successfully leveraged the opportunities in the market. With revenue of more than EUR 1.7 billion and operating profit (EBITDA) of over EUR 247 million, new record figures in Amags’s history were achieved.” The Management and Supervisory boards will propose a stable dividend of EUR 1.50  per share to the Annual General Meeting.
Amag: weekly performance: 4.91%

Uniqa: On basis of preliminary results from preparing the consolidated financial statements of Uniqa Insurance Group AG as at 31 December 2022 Uniqa expects significantly improved consolidated earnings before taxes for the financial year 2022 in the range of EUR 420 million to EUR 425 million (2021: EUR 382.3 million; analyst consensus approx. EUR 364 million).
Uniqa: weekly performance: 1.40%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/02/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Amag, Uniqa (16/02/2023)


19.02.2023, 1919 Zeichen



Marinomed: Marinomed Biotech AG, listed on the Vienna Stock Exchange, achieved a further increase in demand for Carragelose products in 2022. According to preliminary figures, Carragelose revenues were up by 15.5% to € 11.2 m (2021: € 9.7 m). This positive development resulted in stable preliminary revenues of € 11.3 m for the full year (2021: € 11.6 m) despite the lack of milestone payments in 2022. Adjusted for the Budesolv milestone payment of € 1.9 m in 2021, revenues have increased by 16.5 %. Cash and cash equivalents increased to € 8.2 m (2021: € 5.8 m; +41%), reflecting a low cash burn-rate throughout 2022 due to profitable revenues and inflows from loans, real estate financings and the convertible bond program with Nice & Green.
Marinomed Biotech: weekly performance: 7.21%

Amag: Amag Austria Metall AG again achieved record levels of revenue and earnings following record results in the previous year. CEO  Gerald Mayer comments: “With our proven strategic focus on innovation and sustainability and with our expert team, we mastered the challenges over the past year and successfully leveraged the opportunities in the market. With revenue of more than EUR 1.7 billion and operating profit (EBITDA) of over EUR 247 million, new record figures in Amags’s history were achieved.” The Management and Supervisory boards will propose a stable dividend of EUR 1.50  per share to the Annual General Meeting.
Amag: weekly performance: 4.91%

Uniqa: On basis of preliminary results from preparing the consolidated financial statements of Uniqa Insurance Group AG as at 31 December 2022 Uniqa expects significantly improved consolidated earnings before taxes for the financial year 2022 in the range of EUR 420 million to EUR 425 million (2021: EUR 382.3 million; analyst consensus approx. EUR 364 million).
Uniqa: weekly performance: 1.40%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/02/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

SportWoche ÖTV-Spitzentennis Podcast: Die ÖTV/WTA/ATP-Bilanz 2025 und die erste SportWoche-Kultfigur als weiterer Preis für Lilli Tagger




 

Bildnachweis

Aktien auf dem Radar:UBM, Agrana, Zumtobel, Addiko Bank, Austriacard Holdings AG, Palfinger, ATX, ATX Prime, ATX TR, ATX NTR, Bawag, Mayr-Melnhof, RBI, Wienerberger, Lenzing, Rosenbauer, Warimpex, CA Immo, FACC, Wolford, BKS Bank Stamm, Oberbank AG Stamm, VIG, Amag, AT&S, CPI Europe AG, Österreichische Post, voestalpine, Infineon, Merck KGaA, Fresenius Medical Care.


Random Partner

REPLOID Group AG
Die 2020 gegründete REPLOID Group AG stellt hochwertige Proteine und Fette sowie biologischen Dünger aus der Aufzucht von Larven der Schwarzen Soldatenfliege her. In den für ihre Kunden errichteten Mastanlagen – den REPLOID ReFarmUnits – erhalten vom Unternehmen gelieferte Junglarven eine auf den jeweiligen Standort abgestimmte Futtermischung aus Reststoffen der regionalen Lebensmittel-Wertschöpfungskette. Nach erfolgter Mast übernimmt REPLOID die Larven zur zentralen Vermarktung.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten